Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE)

NCT05096091 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.

NCT NCT05096091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05096091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE)
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Phase
Observational
Overall status
Completed
Start date
August 16, 2021
Completion date
August 19, 2025
Enrollment
5,399 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19